z-logo
Premium
A proof‐of‐concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug
Author(s) -
Wallace John L.,
Nagy Peter,
Feener Troy D.,
Allain Thibault,
Ditrói Tamás,
Vaughan David J.,
Muscara Marcelo N.,
Nucci Gilberto,
Buret Andre G.
Publication year - 2020
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.14641
Subject(s) - naproxen , medicine , analgesic , gastroenterology , drug , nausea , toxicity , antipyretic , incidence (geometry) , pharmacology , pathology , alternative medicine , physics , optics
ATB-346 is a hydrogen sulfide (H 2 S)-releasing anti-inflammatory and analgesic drug. Animal studies demonstrated negligible gastrointestinal (GI) damage despite marked inhibition of COX activity and significant analgesic and anti-inflammatory effects. In humans, ATB-346 (250 mg once daily) was found to inhibit COX to the same extent as naproxen (550 mg twice daily).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here